Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2020.570927 http://scihub22266oqcxt.onion/10.3389/fimmu.2020.570927 33123144!7573101!33123144     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2020 ; 11 (ä): 570927 Nephropedia Template TP {{tp|p=33123144|t=2020. SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment |pdf=|usr=}}{{33123144}} gab.com Text SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33123144 #FOAvip The emergence and rapid spread of SARS-CoV-2 in December 2019 has brought the world to a standstill. While less pathogenic than the 2002-2003 SARS-CoV, this novel betacoronavirus presents a global threat due to its high transmission rate, ability to invade multiple tissues, and ability to trigger immunological hyperactivation. The identification of the animal reservoir and intermediate host were important steps toward slowing the spread of disease, and its genetic similarity to SARS-CoV has helped to determine pathogenesis and direct treatment strategies. The exponential increase in cases has necessitated fast and reliable testing procedures. Although RT-PCR remains the gold standard, it is a time-consuming procedure, paving the way for newer techniques such as serologic tests and enzyme immunoassays. Various clinical trials using broad antiviral agents in addition to novel medications have produced controversial results; however, the advancement of immunotherapy, particularly monoclonal antibodies and immune modulators is showing great promise in clinical trials. Non-orthodox medications such as anti-malarials have been tested in multiple institutions but definitive conclusions are yet to be made. Adjuvant therapies have also proven to be effective in decreasing mortality in the disease course. While no formal guidelines have been established, the multitude of ongoing clinical trials as a result of unprecedented access to research data brings us closer to halting the SARS-CoV-2 pandemic. Twit Text FOAVip SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33123144 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33123144 #FOAvip English Wikipedia <ref>{{Cite pmid|33123144}}</ref> SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment #MMPMID33123144 Khalaf K; Papp N; Chou JT; Hana D; Mackiewicz A; Kaczmarek M Front Immunol 2020[]; 11 (ä): 570927 PMID33123144show ga The emergence and rapid spread of SARS-CoV-2 in December 2019 has brought the world to a standstill. While less pathogenic than the 2002-2003 SARS-CoV, this novel betacoronavirus presents a global threat due to its high transmission rate, ability to invade multiple tissues, and ability to trigger immunological hyperactivation. The identification of the animal reservoir and intermediate host were important steps toward slowing the spread of disease, and its genetic similarity to SARS-CoV has helped to determine pathogenesis and direct treatment strategies. The exponential increase in cases has necessitated fast and reliable testing procedures. Although RT-PCR remains the gold standard, it is a time-consuming procedure, paving the way for newer techniques such as serologic tests and enzyme immunoassays. Various clinical trials using broad antiviral agents in addition to novel medications have produced controversial results; however, the advancement of immunotherapy, particularly monoclonal antibodies and immune modulators is showing great promise in clinical trials. Non-orthodox medications such as anti-malarials have been tested in multiple institutions but definitive conclusions are yet to be made. Adjuvant therapies have also proven to be effective in decreasing mortality in the disease course. While no formal guidelines have been established, the multitude of ongoing clinical trials as a result of unprecedented access to research data brings us closer to halting the SARS-CoV-2 pandemic. |*Coronavirus Infections/diagnosis/pathology/therapy[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/diagnosis/pathology/therapy[MESH] |Adenosine Monophosphate/analogs & derivatives/therapeutic use[MESH] |Alanine/analogs & derivatives/therapeutic use[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Antibodies, Monoclonal/therapeutic use[MESH] |Antibodies, Viral/therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |Betacoronavirus/*drug effects/genetics/immunology[MESH] |COVID-19[MESH] |COVID-19 Testing[MESH] |Clinical Laboratory Techniques/*methods[MESH] |Disease Reservoirs/virology[MESH] |Drug Repositioning/methods[MESH] |Humans[MESH] |Immunoenzyme Techniques[MESH] |Immunotherapy[MESH] |Peptidyl-Dipeptidase A/metabolism[MESH] |Receptors, Virus/metabolism[MESH] |Reverse Transcriptase Polymerase Chain Reaction[MESH] |SARS-CoV-2[MESH] |Serologic Tests/methods[MESH]SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatmen(epmc).pdf DeepDyve Pubget Overpricing